Meeting
2022 ASCO Gastrointestinal Cancers Symposium
Role of an anti-gastrin vaccine (PAS) alone and in combination with a PD-1 antibody on growth and metastases of gastric cancer.
Authors
Jill P Smith
Georgetown University, Department of Medicine, Washington, DC
Jill P Smith , Hong Cao , Wenqiang Chen , Kanwal Mahmood , Teresa Phillips , Lynda Youngpeter Sutton , Allen Cato
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Cancers of the Esophagus and Stomach and Other GI Cancers
Track
Esophageal and Gastric Cancer,Other GI Cancer
Sub Track
Translational Research
DOI
10.1200/JCO.2022.40.4_suppl.334
Abstract #
334
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Gastrointestinal Cancers Symposium
nextHERIZON: A phase 2 study of HER-Vaxx, a HER2-targeting peptide vaccine, in combination with chemotherapy or pembrolizumab in patients with HER2 metastatic or advanced gastric/gastroesophageal adenocarcinoma that progressed on or after trastuzumab treatment.
First Author: Timothy Jay Price
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Phase II study (daNIS-1) of the anti–TGF-β monoclonal antibody (mAb) NIS793 with and without the PD-1 inhibitor spartalizumab in combination with nab-paclitaxel/gemcitabine (NG) versus NG alone in patients (pts) with first-line metastatic pancreatic ductal adenocarcinoma (mPDAC).
First Author: Li-Yuan Bai
Poster
2022 ASCO Annual Meeting
Phase II study (daNIS-1) of the anti-TGF-β monoclonal antibody (mAb) NIS793 with and without the PD-1 inhibitor spartalizumab in combination with nab-paclitaxel/gemcitabine (NG) versus NG alone in patients (pts) with first-line metastatic pancreatic ductal adenocarcinoma (mPDAC).
First Author: Li-Yuan Bai
Poster
2021 ASCO Annual Meeting
Phase II study of the anti-TGF-β monoclonal antibody (mAb) NIS793 with and without the PD-1 inhibitor spartalizumab in combination with nab-paclitaxel/gemcitabine (NG) versus NG alone in patients (pts) with first-line metastatic pancreatic ductal adenocarcinoma (mPDAC).
First Author: Peter Grell